Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Reads0
Chats0
TLDR
Several glutamate receptor-modulating agents have been tested in proof-of-concept studies for mood disorders as discussed by the authors, and most have shown relatively modest effects compared with (R,S)-ketamine and esketamine, though some have shown more favorable characteristics.Abstract:
The efficacy of standard antidepressants is limited for many patients with mood disorders such as major depressive disorder (MDD) and bipolar depression, underscoring the urgent need to develop novel therapeutics. Both clinical and preclinical studies have implicated glutamatergic system dysfunction in the pathophysiology of mood disorders. In particular, rapid reductions in depressive symptoms have been observed in response to subanesthetic doses of the glutamatergic modulator racemic (R,S)-ketamine in individuals with mood disorders. These results have prompted investigation into other glutamatergic modulators for depression, both as monotherapy and adjunctively. Several glutamate receptor-modulating agents have been tested in proof-of-concept studies for mood disorders. This manuscript gives a brief overview of the glutamate system and its relevance to rapid antidepressant response and discusses the existing clinical evidence for glutamate receptor-modulating agents, including (1) broad glutamatergic modulators ((R,S)-ketamine, esketamine, (R)-ketamine, (2R,6R)-hydroxynorketamine [HNK], dextromethorphan, Nuedexta [a combination of dextromethorphan and quinidine], deudextromethorphan [AVP-786], axsome [AXS-05], dextromethadone [REL-1017], nitrous oxide, AZD6765, CLE100, AGN-241751); (2) glycine site modulators (d-cycloserine [DCS], NRX-101, rapastinel [GLYX-13], apimostinel [NRX-1074], sarcosine, 4-chlorokynurenine [4-Cl-KYN/AV-101]); (3) subunit (NR2B)-specific N-methyl-d-aspartate (NMDA) receptor antagonists (eliprodil [EVT-101], traxoprodil [CP-101,606], rislenemdaz [MK-0657/CERC-301]); (4) metabotropic glutamate receptor (mGluR) modulators (basimglurant, AZD2066, RG1578, TS-161); and (5) mammalian target of rapamycin complex 1 (mTORC1) activators (NV-5138). Many of these agents are still in the preliminary stages of development. Furthermore, to date, most have demonstrated relatively modest effects compared with (R,S)-ketamine and esketamine, though some have shown more favorable characteristics. Of these novel agents, the most promising, and the ones for which the most evidence exists, appear to be those targeting ionotropic glutamate receptors.read more
Citations
More filters
Journal ArticleDOI
The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents
Christoph U. Correll,Marco Solmi,Samuele Cortese,Maurizio Fava,Mikkel Højlund,Helena C. Kraemer,Roger S. McIntyre,Daniel S. Pine,Lon S. Schneider,John M. Kane +9 more
TL;DR: The most promising drugs with innovative mechanisms of action are undergoing phase 2 or 3 testing for schizophrenia, bipolar disorder, major depressive disorder, anxiety and trauma-related disorders, substance use disorders, and dementia as mentioned in this paper .
Journal ArticleDOI
Ketamine treatment for depression: a review
TL;DR: This paper reviewed the clinical evidence regarding single-dose intravenous (IV) administration of the novel glutamatergic modulator racemic (R,S)-ketamine (hereafter referred to as ketamine) as well as its S-enantiomer, intranasal esketamine, for the treatment of major depressive disorder (MDD).
Journal ArticleDOI
Novel drug developmental strategies for treatment‐resistant depression
TL;DR: The most promising approaches are inhibition of glutamatergic neurotransmission by NMDA and mGlu5 receptor antagonists, modulation of the opioidergic system by κ receptor antagonists and hallucinogenic tryptamine derivates as discussed by the authors .
Journal ArticleDOI
Ketamine activates adult-born immature granule neurons to rapidly alleviate depression-like behaviors in mice
TL;DR: In this article , the authors demonstrate that activity of adult-born immature granule neurons (ABINs) in the mouse hippocampal dentate gyrus is both necessary and sufficient for the rapid antidepressant effects of ketamine.
Journal ArticleDOI
Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression.
TL;DR: In this paper, a review summarizes the pathophysiology of major depressive disorder found in the glutamate system, exploring the role of glutamate receptors and their downstream effects, and further insight into the mechanism of depression and exploring potential targets for novel agent development.
References
More filters
Journal ArticleDOI
Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder: A Randomized Clinical Trial
Adriana Feder,Michael K. Parides,James W. Murrough,Andrew M. Perez,Julia E. Morgan,Shireen Saxena,Katherine A. Kirkwood,Marije aan het Rot,Kyle A.B. Lapidus,Le Ben Wan,Dan V. Iosifescu,Dennis S. Charney +11 more
TL;DR: This study provides the first evidence for rapid reduction in symptom severity following ketamine infusion in patients with chronic PTSD, and may lead to novel approaches to the pharmacologic treatment of patients with this disabling condition.
Journal ArticleDOI
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Chun Yang,Yukihiko Shirayama,Yukihiko Shirayama,Jiancheng Zhang,Qian Ren,Wei Yao,Min Ma,Chao Dong,Kenji Hashimoto +8 more
TL;DR: In the social defeat stress and learned helplessness models of depression, R-ketamine showed a greater potency and longer-lasting antidepressant effect than S-ketamines (esketamine), and findings suggest that, unlike S- ketamine, R -ketamine can elicit a sustained antidepressant effect, mediated by increased BDNF–TrkB signaling and synaptogenesis in the PFC, DG and CA3.
Journal ArticleDOI
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis
Samuel T. Wilkinson,Elizabeth D. Ballard,Michael H. Bloch,Sanjay J. Mathew,James W. Murrough,Adriana Feder,P. Sos,Gang Wang,Carlos A. Zarate,Gerard Sanacora +9 more
TL;DR: Ketamine rapidly reduced suicidal thoughts, within 1 day and for up to 1 week in depressed patients with suicidal ideation, although subsequent trials in transdiagnostic samples are required to confirm that ketamine exerts a specific effect on suicidal Ideation.
Journal ArticleDOI
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial
Ella Daly,Jaskaran Singh,Maggie Fedgchin,Kimberly Cooper,Pilar Lim,Richard C. Shelton,Michael E. Thase,Andrew Winokur,Luc Van Nueten,Husseini K. Manji,Wayne C. Drevets +10 more
TL;DR: In this first clinical study to date of intranasal esketamine for TRD, antidepressant effect was rapid in onset and dose related and response appeared to persist for more than 2 months with a lower dosing frequency.
Journal ArticleDOI
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.
Gerard Sanacora,Mark A. Frye,William M. McDonald,Sanjay J. Mathew,Sanjay J. Mathew,Mason S. Turner,Alan F. Schatzberg,Paul Summergrad,Charles B. Nemeroff +8 more
TL;DR: Information is provided on potentially important issues related to the off-label treatment approach of ketamine that should be considered to help ensure patient safety and the limitations of the available data.